Skip to content

Startups

PhaseRx

Startup thumbnail placeholder image

Sectors
Health & Medicine

Launched
01/01/2007

Description

PhaseRx is developing RNA nanomedicines for the treatment of orphan diseases. The Company’s innovative approach to drug discovery and development is based on its proprietary SMARTT Polymer Technology®, which offers effective mRNA delivery, a favorable side effect profile and robust and scalable manufacture.

Team Members

Robert Overell

President and CEO

Paul Johnson

Chief Scientific Officer

Michael Houston

VP of Therapeutics Development

Mary Prieve

Director of Biology

Sean Monahan

Director of Chemistry